Human prostate MRI at ultrahigh‐performance gradient: A feasibility study
Magnetic Resonance in Medicine · 2024
DOI: 10.1002/mrm.29874 ↗Kurz gefasst
Fachartikel in der Zeitschrift Magnetic Resonance in Medicine, 2024. Verfasst von Ante Zhu und 12 weiteren Autor:innen. Beteiligte Einrichtung: GE Research, Niskayuna, New York, USA. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Prostatic Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIBIB NIH HHS, NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Purpose
To demonstrate the technical feasibility and the value of ultrahigh‐performance gradient in imaging the prostate in a 3T MRI system.
Methods
In this local institutional review board–approved study, prostate MRI was performed on 4 healthy men. Each subject was scanned in a prototype 3T MRI system with a 42‐cm inner‐diameter gradient coil that achieves a maximum gradient amplitude of 200 mT/m and slew rate of 500 T/m/s. PI‐RADS V2.1–compliant axial T 2 ‐weighted anatomical imaging and single‐shot echo planar DWI at standard gradient of 70 mT/m and 150 T/m/s were obtained, followed by DWI at maximum performance (i.e., 200 mT/m and 500 T/m/s). In comparison to state‐of‐the‐art clinical whole‐body MRI systems, the high slew rate improved echo spacing from 1020 to 596 μs and, together with a high gradient amplitude for diffusion encoding, TE was reduced from 55 to 36 ms.
Results
In all 4 subjects (waist circumference = 81–91 cm, age = 45–65 years), no peripheral nerve stimulation sensation was reported during DWI. Reduced image distortion in the posterior peripheral zone prostate gland and higher signal intensity, such as in the surrounding muscle of high‐gradient DWI, were noted.
Conclusion
Human prostate MRI at simultaneously high gradient amplitude of 200 mT/m and slew rate of 500 T/m/s is feasible, demonstrating that improved gradient performance can address image distortion and T 2 decay–induced SNR issues for in vivo prostate imaging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- GE Research, Niskayuna, New York, USA.
- Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- GE Healthcare, New York, New York, USA.
- Medical Radiation Physics, Clinical Sciences Lund, Lund University, Lund, Sweden.
ORCID-Profile: Ante Zhu, Matthew Tarasek, Yousef Mazaheri
Förderung
- NIBIB NIH HHS
- NIH HHS
- NCI NIH HHS
- Massachusetts Life Sciences Center
- National Institutes of Health
- Cancerfonden
Zitieren
APA
Zhu, A., Tarasek, M., Hua, Y., Fiveland, E., Maier, S. E., Mazaheri, Y., Fung, M., Westin, C. F., Yeo, D. T. B., Szczepankiewicz, F., Tempany, C., Akin, O., & Foo, T. K. F. (2024). Human prostate MRI at ultrahigh‐performance gradient: A feasibility study. Magnetic Resonance in Medicine. https://doi.org/10.1002/mrm.29874
Vancouver
Zhu A, Tarasek M, Hua Y, Fiveland E, Maier SE, Mazaheri Y, et al. Human prostate MRI at ultrahigh‐performance gradient: A feasibility study. Magnetic Resonance in Medicine. 2024. doi:10.1002/mrm.29874
BibTeX
@article{Zhu2024,
author = {Zhu, Ante and Tarasek, Matthew and Hua, Yihe and Fiveland, Eric and Maier, Stephan E and Mazaheri, Yousef and Fung, Maggie and Westin, Carl-Fredrik and Yeo, Desmond T B and Szczepankiewicz, Filip and Tempany, Clare and Akin, Oguz and Foo, Thomas K F},
title = {Human prostate MRI at ultrahigh‐performance gradient: A feasibility study},
journal = {Magnetic Resonance in Medicine},
year = {2024},
doi = {10.1002/mrm.29874}
}
EUVIMED